Trial Profile
24 Month Open Label Study of the Tolerability and Efficacy of an Antisense Oligonucleotide (Inotersen) in Patients With Transthyretin (TTR) Amyloid Cardiomyopathy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2022
Price :
$35
*
At a glance
- Drugs Inotersen (Primary)
- Indications Amyloidosis; Cardiomyopathies
- Focus Therapeutic Use
- 03 Dec 2020 Status changed from recruiting to active, no longer recruiting.
- 31 Jul 2019 Planned End Date changed from 1 Dec 2021 to 1 Mar 2022.
- 31 Jul 2019 Planned primary completion date changed from 1 Jun 2021 to 1 Jan 2022.